Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
8-31-2021

Vesicular stomatitis virus chimeras expressing the oropouche
virus glycoproteins elicit protective immune responses in mice
Sarah Hulsey Stubbs
Marjorie Cornejo Pontelli
Nischay Mishra
Changhong Zhou
Juliano de Paula Souza

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Authors
Sarah Hulsey Stubbs, Marjorie Cornejo Pontelli, Nischay Mishra, Changhong Zhou, Juliano de Paula
Souza, Rosa Maria Mendes Viana, W Ian Lipkin, David M Knipe, Eurico Arruda, and Sean P J Whelan

RESEARCH ARTICLE

Vesicular Stomatitis Virus Chimeras Expressing the Oropouche
Virus Glycoproteins Elicit Protective Immune Responses in Mice
Sarah Hulsey Stubbs,a Marjorie Cornejo Pontelli,b Nischay Mishra,c Changhong Zhou,a Juliano de Paula Souza,d
Rosa Maria Mendes Viana,d W. Ian Lipkin,c David M. Knipe,a Eurico Arruda,d Sean P. J. Whelanb
Department of Microbiology, Harvard Medical School, Boston, Massachusetts, USA

a

Department of Molecular Microbiology, Washington University School of Medicine in St. Louis, Saint Louis, Missouri, USA

b
c

Center for Infection and Immunity, Mailman School of Public Health, Columbia University, New York, New York, USA
Department of Cell and Molecular Biology, Virology Research Center, Ribeirao Preto School of Medicine, University of São Paulo, Ribeirao Preto, São Paulo, Brazil

d

Oropouche virus (OROV) infection of humans is associated with a debilitating febrile illness that can progress to meningitis or encephalitis. First isolated from a forest worker in Trinidad and Tobago in 1955, the arbovirus OROV has since been detected
throughout the Amazon basin with an estimated 500,000 human infections over
60 years. Like other members of the family Peribunyaviridae, the viral genome exists as 3
single-stranded negative-sense RNA segments. The medium-sized segment encodes a viral glycoprotein complex (GPC) that is proteolytically processed into two viral envelope
proteins, Gn and Gc, responsible for attachment and membrane fusion. There are no
therapeutics or vaccines to combat OROV infection, and we have little understanding of
protective immunity to infection. Here, we generated a replication competent chimeric
vesicular stomatitis virus (VSV), in which the endogenous glycoprotein was replaced by
the GPC of OROV. Serum from mice immunized by intramuscular injection with VSVOROV speciﬁcally neutralized wild-type OROV, and using peptide arrays we mapped
multiple epitopes within an N-terminal variable region of Gc recognized by the immune
sera. VSV-OROV lacking this variable region of Gc was also immunogenic in mice producing neutralizing sera that recognize additional regions of Gc. Challenge of both sets
of immunized mice with wild-type OROV shows that the VSV-OROV chimeras reduce
wild-type viral infection and suggest that antibodies that recognize the variable N terminus of Gc afford less protection than those that target more conserved regions of Gc.

IMPORTANCE Oropouche virus (OROV), an orthobunyavirus found in Central and South
America, is an emerging public health challenge that causes debilitating febrile illness.
OROV is transmitted by arthropods, and increasing mobilization has the potential to
signiﬁcantly increase the spread of OROV globally. Despite this, no therapeutics or vaccines have been developed to combat infection. Using vesicular stomatitis (VSV) as a
backbone, we developed a chimeric virus bearing the OROV glycoproteins (VSV-OROV)
and tested its ability to elicit a neutralizing antibody response. Our results demonstrate
that VSV-OROV produces a strong neutralizing antibody response that is at least partially targeted to the N-terminal region of Gc. Importantly, vaccination with VSV-OROV
reduces viral loads in mice challenged with wild-type virus. These data provide novel
evidence that targeting the OROV glycoproteins may be an effective vaccination strategy to combat OROV infection.
KEYWORDS Oropouche virus, arbovirus, bunyavirus, emerging infectious diseases,

vaccines
ropouche virus (OROV), ﬁrst isolated in 1955 from a forest worker in Trinidad and
Tobago, causes a debilitating febrile illness in humans that can progress to meningitis or encephalitis (1, 2). OROV is the most prevalent arbovirus after dengue in Brazil
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(3, 4) and is currently circulating in Argentina, Bolivia, Colombia, Ecuador, and
Venezuela (5–7). In urban areas across the Amazon region, seroprevalence rates of up
to 15 to 33% suggest that OROV infection is underappreciated (8, 9). The virus infects a
broad range of species and has both a sylvatic and an urban cycle. During the sylvatic
cycle, the virus infects sloths, monkeys, rodents, and birds, with Coquillettidia venezuelensis and Ochlerotatus serratus serving as vectors (1). In the urban cycle, Culicoides paraensis and Culex quinquefasciatus serve as vectors of OROV (1), with human infections
paralleling increases in the vector population during the rainy season (10). Infection is
predominantly seen in individuals returning from forested areas (11), with limited evidence of direct human to human transmission (12). Climate change, expansion and dissemination of vectors, globalization of travel, and habitat loss likely contribute to
increases in OROV infections (13). Despite the growing dissemination of OROV, and the
risks posed by this emergent threat, there are currently no therapeutics to combat
OROV infection.
Oropouche virus, a member of the family Peribunyaviridae, contains a single-stranded,
negative-sense RNA genome divided on three segments providing a total genome size of
11,985 nucleotides. The large segment (l) encodes the large protein (L), which acts as the
RNA-dependent RNA polymerase, the medium segment (m) encodes the viral glycoprotein complex (GPC), and the small segment (s) encodes the nucleocapsid protein that
sheaths the genomic and antigenomic RNA. Two nonstructural proteins, NSs and NSm
are coded by the small and medium segments, respectively. The GPC is synthesized as a
single polyprotein that undergoes cotranslational cleavage by host-cell proteases into
the two glycoproteins, Gn and Gc, and liberates the intervening NSm protein (14). The
Gc protein acts as the viral fusogen (15), and Gn mediates attachment and shields and
protects Gc from premature triggering (16). Extrapolating from studies with La Crosse
(17–20) and Schmallenberg (16, 21) viruses, both in the same orthobunyavirus genus of
the Peribunyaviridae, antibodies against the glycoproteins may protect against infection
and are therefore an important objective of vaccine strategies against OROV.
Vesicular stomatitis virus (VSV), the prototype of the family Rhabdoviridae, infects cells
by a single attachment and fusion glycoprotein (G) (22). The development of reverse
genetic approaches to manipulate the VSV genome (23) permitted replacement of the
attachment and fusion machinery with those of heterologous lipid enveloped viruses
(24–28). In the case of Zaire ebolavirus, the resulting VSV-ZEBOV chimera is a live attenuated vaccine, ERVEBO, that is approved for use in humans (29–31). Analogous vaccine
candidates are in preclinical and clinical development for multiple enveloped viruses (25,
27, 32), including severe acute respiratory syndrome 2 coronavirus (33). In addition to providing a platform for development of candidate vaccines, the VSV-chimeric viruses have
also permitted investigation of viral tropism and cellular entry pathways and helped us
understand correlates of immune protection (30, 34–38).
Building on this proven approach, we generated a VSV-chimera in which the native
glycoprotein gene is replaced by the GPC of OROV. The resulting VSV-OROV chimera
replicates to high titers in BSRT7 cells in culture and efﬁciently incorporates the Gn and
Gc of OROV into particles. Following single-dose or prime-boost intramuscular injection of mice, VSV-OROV elicits the production of immune-speciﬁc sera that neutralize
wild-type OROV. Using peptide arrays corresponding to the OROV glycoproteins, we
ﬁnd signiﬁcant reactivity to the more variable N-terminal domain of Gc that precedes
the domains that are structurally homologous to other class II fusion proteins. We generated two additional VSV-OROV chimeras lacking portions of the variable N terminus
of Gc, termed the “head” and “stalk” domains. Although both variants yielded replication competent virus, deletion of the stalk domain led to the accumulation of mutations in Gc. Immunization of mice with the VSV-OROV lacking the head domain of Gc
generated immune sera reactive with new regions of Gc. Challenge studies demonstrate that immunization with VSV-OROV or the chimera lacking the head domain of
Gc offers protection against wild-type OROV infection as evidenced by weight loss,
temperature, and viral burden. This study demonstrates that VSV-OROV immunization
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induces neutralizing serum responses that can protect mice against challenge with
wild-type OROV.
RESULTS
Construction and characterization of VSV-Oropouche chimeras. Orthobunyavirus
virions incorporate two viral glycoproteins on their surface, Gn and Gc, that mediate
binding and entry into the cell. Gn and Gc are synthesized as part of a polyprotein precursor GPC. We engineered an infectious molecular clone of VSV that expresses
enhanced green ﬂuorescent protein (eGFP) as a marker of infection (39), to replace the
native attachment and fusion glycoprotein with the GPC polyprotein of OROV (Fig. 1A).
Using established procedures, we recovered a chimeric virus, VSV-OROV, capable of autonomous replication as evidenced by plaque formation (Fig. 1A). Kinetic analysis of
the yields of infectious VSV-OROV identify a 1-log reduction in viral growth compared
to VSV-eGFP (Fig. 1A). Analysis of the protein composition of puriﬁed virions by SDSPAGE demonstrates that Gn and Gc are incorporated into VSV-OROV in place of VSV G
(Fig. 1B). Mass spectrometry analysis of the band above P in the VSV-OROV sample
identiﬁed the band as an albumin contaminant. VSV-OROV particles retain the classic
bullet shape of VSV as evidenced by negative-stain electron microscopy and are visually decorated with spikes consistent with incorporation of the OROV glycoproteins
(Fig. 1C). As insertion of the M open reading frame (ORF) of OROV increases the genome length of VSV by approximately 2,500 nucleotides, the VSV-OROV particles are
approximately 34 nm longer than VSV particles and 11 nm narrower (Fig. 1D).
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FIG 1 Generation and characterization of VSV-OROV. (A) Genomic organization of VSV-eGFP and VSV-OROV.
Viral genomes are shown in the 39 to 59 orientation. The ﬁve viral genes, N (nucleocapsid), P (phosphoprotein),
M (matrix), G (glycoprotein), and L (large polymerase), are shown. Enhanced green ﬂuorescent protein (eGFP) is
located in the ﬁrst position and serves as a marker for infection. The VSV glycoprotein was replaced with the
gene encoding the OROV M segment to generate VSV-OROV. Representative plaque assays are shown on the
right as well as the endpoint titers in BSRT7 cells. (B) SDS-PAGE analysis of puriﬁed virions stained with
Coomassie blue. Viral proteins are indicated on the right. (C) Electron micrographs of puriﬁed virions stained
with 2% PTA. (D) Measurements of individual viral particles were carried out from micrographs like those
shown in panel C. Each circle represents a single virion, and the line denotes the mean with the standard
deviation (n = 35). Length and width differences between VSV and VSV-OROV particles were statistically
signiﬁcant; ****, P , 0.0001.
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Effect of truncation of the OROV Gc N-terminal variable region on viral
infectivity. For the orthobunyavirus, bunyamwera (BUNV), the N-terminal half of Gc is
dispensable for viral replication in cell culture (40). Phylogenetic analysis suggests the N
terminus of Gc comprises two variable domains that have novel folds, and recent structural studies reveal that those variable domains correspond to a head and stalk domains
of Gc (16). Deletion of the head domain results in enhanced cell fusion for BUNV, suggesting that this region may act to mask or protect the highly conserved fusion peptide (40).
Elimination of the head and stalk domain resulted in a further reduction in viral yield,
although the mechanism underlying this is unclear (40). Using the infectious cDNA of
VSV-OROV, we engineered the analogous variants lacking the head domain of Gc (VSVOROVD4) or the head and stalk domains (VSV-OROVD8). Autonomously replicating
viruses were recovered from both variants (Fig. 2A). Sequence analysis demonstrates that
no other changes were present in the GPC gene of VSV-OROV or VSV-OROVD4, but each
of the VSV-OROVD8 isolates sequenced contained additional mutations in Gc (Fig. 2B),
with three of the variants containing premature stop codons in the Gc cytoplasmic tail.
Although growth of both truncated variants was attenuated compared to VSV-OROV,
VSV-OROVD4 reached comparable titers (Fig. 2C). This result demonstrates that as for
BUNV, at least a portion of the N terminus of Gc is dispensable for infectivity of cells mediated by the glycoprotein complex of OROV.
VSV-OROV chimeras elicit production of neutralizing antibodies in mice. To determine whether the VSV-OROV chimeras were immunogenic, we inoculated BALB/c mice
intramuscularly with VSV or the indicated VSV-OROV chimera, boosted the animals
28 days later, and examined serum-neutralizing titers at days 27 and 35 postinoculation
(Fig. 3A). Inoculation of mice with VSV-OROV generates sera that speciﬁcally neutralize
VSV-OROV but not VSV, as measured by cell culture infection assays. Correspondingly,
sera from mice inoculated with VSV speciﬁcally neutralize VSV but not VSV-OROV, validating that neutralization depends on the surface glycoproteins and not other components of the virion (Fig. 3B). All mice produced antibodies capable of neutralizing the
relevant virus, whereas sera from sham-vaccinated animals failed to neutralize either
VSV-OROV or VSV. Mice inoculated with VSV-OROVD4 generated sera that neutralized
both VSV-OROV and VSV-OROVD4 (Fig. 3C). The increased sensitivity of VSV-OROVD4
to neutralization suggests loss of the head domain may increase accessibility of important neutralizing epitopes.
To examine the ability of the mouse sera to neutralize wild-type OROV, we tested serum samples from the 5 individual mice using a plaque reduction neutralization titer
assay (Fig. 3D). Consistent with the ability of the sera to neutralize the respective VSV-chimeras, mice that generated neutralizing antibodies against VSV-OROV neutralized wildtype OROV, showing 50% decreases in infectivity at serum dilutions of .1:200 to 1:1,600.
Consistent with the observed neutralization of the VSV-chimeras, sera from mice inoculated with VSV-OROVD4 were more potent than those inoculated with VSV-OROV, and serum from each mouse exhibited a .50% inhibition of infection at dilutions of 1:400 to
1:3,200 (Fig. 3D). We conclude that VSV-OROV results in production of sera that neutralize
wild-type virus and that deletion of the N-terminal portion of Gc further increases neutralizing titers, perhaps by targeting additional epitopes.
VSV-OROV and VSV-OROVD4 sera generate antibodies to both Gn and Gc. To
identify epitopes recognized by the serum from each immunized mouse, we utilized peptide arrays designed to detect antibodies targeting linear epitopes. The tiled array is composed of ;170,000 nonredundant 12-mer peptides from seven arboviruses, including
OROV (41), and is formatted in a sliding window pattern such that there is an 11-amino
acid overlap along the peptide sequence of each virus. The peptides are randomly distributed across the array to prevent location bias. This peptide array was previously used to
diagnose Zika virus infection and identiﬁed a highly speciﬁc Zika epitope within the NS2B
protein (41). Proﬁling of the sera from each mouse inoculated with VSV-OROV identiﬁed 4
peptides in a 150-residue region of the ectodomain of Gc, with two of the peptides overlapping by 6 amino acids (Fig. 4A and B). This region of Gc corresponds to the N-terminal
head domain of the variable region of Gc (16) (Fig. 4C).
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FIG 2 Generation of VSV-OROV chimeras and mutants. (A) Genomic organization of VSV-OROV, VSVOROVD4, and VSV-OROVD8. Amino acids 484 to 698 were deleted from the N-terminal region of Gc

(Continued on next page)
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Mice immunized with VSV-OROVD4, lacking the N-terminal region of Gc, generated
immune sera that reacted with linear epitopes that target both Gn and Gc of OROV.
Speciﬁcally, we identiﬁed one peptide at the N terminus of Gn and six epitopes distributed throughout Gc. Five of the six Gc peptides are located N-terminal to the fusion
peptide, with 1 peptide mapping approximately 100 residues to the C terminus of the
fusion peptide. No conserved peptides were identiﬁed across both arrays. Earlier work
with Bunyamwera virus deﬁned the C-terminal half of Gc as important for cell fusion
and for interaction of Gc and Gn for trafﬁcking through the Golgi (40). When aligned
with Gc, two of the ﬁve peptides, 974 to 989 and 1159 to 1176, map to the C-terminal
half of Gc. These data demonstrate that removal of the N-terminal head domain of Gc
does not impact the ability of mice to generate neutralizing sera to VSV-OROV and that
linear epitopes are generated that target both Gn and Gc.
Effect of immunization with VSV-OROV chimeras on challenge with wild-type
OROV. To determine whether VSV-OROV can elicit a protective immune response, we
employed a 2-dose prime-boost immunization regimen followed by a wild-type virus
challenge. Brieﬂy, groups of mice (n = 5) received intramuscular inoculation of 106 infectious units of VSV, VSV-OROV, or VSV-OROVD4 and an equivalent immunization
28 days later. Animals were challenged 7 days later with 106 50% tissue culture infective dose (TCID50) of wild-type virus through subcutaneous injection, which most
closely simulates insect bites, and their weights and temperatures were examined
daily. At 7 days postchallenge, the levels of viral RNA in the blood and brain were
examined using a quantitative reverse transcription PCR (qRT-PCR) assay (Fig. 5A). Mice
immunized with VSV or given phosphate-buffered saline (PBS) as a sham lost 5 to 10%
body weight and exhibited a spike in body temperature following challenge. In contrast, animals immunized with VSV-OROV or VSV-OROVD4 continued to increase in
body weight postchallenge and were not febrile (Fig. 5B). We conﬁrmed that mice
immunized with this 2-dose regimen of the VSV-OROV chimeras have high neutralizing
serum titers against OROV 1 day prior to challenge, whereas the VSV- or sham-vaccinated animals had no detectable neutralizing titers (Fig. 5C).
To examine the extent of protection against infection upon challenge, we examined
viral S segment RNA levels by qRT-PCR 7 days postchallenge. We detected S segment
RNA copies in the blood of all groups of challenged animals, although levels were lowest in the VSV-OROVD4-immunized mice. This result demonstrates that the animals develop a viremia following challenge with wild-type virus in the face of a neutralizing serum response (Fig. 5D). While both VSV-OROV- and VSV-OROVD4-immunized mice had
reduced viremia compared to VSV-immunized mice, VSV-OROVD4 viremia was reduced
almost 3-fold compared to VSV-OROV-immunized mice. Analysis of brain tissue demonstrates that mice immunized with VSV-OROVD4 have reduced viral RNA levels compared with naive mice (Fig. 5D), consistent with reduced OROV infection. Analysis of
individual mouse viral loads showed that mice immunized with VSV-OROV or VSVOROVD4 had decreased levels of viral RNA in brain tissues compared with blood samples, while naive and VSV-vaccinated mice did not show this trend.
DISCUSSION
We report three VSV-chimeric viruses expressing the surface proteins Gn and Gc of the
emerging orthobunyavirus, Oropouche, and evaluate those chimeras for immunogenicity
and protection against challenge in a mouse model of disease. The VSV chimeras are highly
immunogenic in mice, yielding serum-neutralizing titers of up to 1:6,400 against wild-type
OROV following a 2-dose intramuscular immunization regimen. Using overlapping peptide

FIG 2 Legend (Continued)
to generate VSV-OROVD4, and amino acids 484 to 870 were deleted to generate VSV-OROVD8.
Plaque assays of VSV-OROV (shown also in Fig. 1) and VSV-OROVD4 on BSRT7 cells are shown on the
right. (B) VSV-OROVD8 isolates were passaged on BSRT7 cells, and the M segments from 5 isolates
were sequenced by Sanger sequencing. Mutations found in the M segment are denoted on the right.
(C) Growth curve of VSV, VSV-OROV, VSV-OROVD4, and VSV-OROVD8 Q1030*.
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FIG 3 Inoculation of mice with VSV recombinants bearing OROV glycoproteins generates neutralizing antibodies. (A) Inoculation schedule
of BALB/c mice. Animals (n = 5 per group) were immunized intramuscularly with VSV-eGFP, VSV-OROV, or VSV-OROVD4 and then boosted
on day 28. Mice were sacriﬁced on day 35, and serum was collected. (B) Reciprocal dilutions of VSV or VSV-OROV serum that protects cells
from 100 TCID50 units of indicated viruses are shown (n = 3). (C) Reciprocal dilution of VSV or VSV-OROVD4 serum that protects cells from

(Continued on next page)
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arrays, we demonstrate that neutralizing sera include antibodies that recognize peptides in
the highly variable N terminus of Gc and demonstrate that elimination of this region results
in sera that recognize more conserved regions of Gc. Challenge studies demonstrate that
immunized mice are infected, although they exhibit reduced clinical symptoms and viral
loads. This work demonstrates that neutralizing antisera offer some protection against
Oropouche infection and provides new biosafety level 2 (BSL2) tools that can be used to
understand the functions of Gn and Gc.
The spread of Oropouche virus in the Amazon region has prompted efforts to
advance countermeasures against infection. The IMP dehydrogenase inhibitor, ribavirin, has no efﬁcacy against OROV (42), and although innate immune responses control infection of mice by OROV (43), interferon alpha (IFN-a) treatment offers only limited protection of mice when administered within 3 h of infection (42, 44). Earlier
efforts to develop vaccines for OROV have included deletion of the NSs and NSm proteins in infectious molecular clones of OROV (3). A similar strategy shows promise for
Schmallenberg virus (SBV), an orthobunyavirus that infects ruminants (45). Although
correlates of immunity are not completely understood for many bunyaviruses, vaccines
targeting the glycoproteins appear to illicit strong immune responses for at least some
bunyaviruses. DNA vaccines expressing Gn and Gc protected mice from challenge with
Rift Valley fever virus (RVFV), while Gn and Gc of Crimean-Congo hemorrhagic fever
orthonairovirus (CCHFV) were not sufﬁcient to confer protection (46). Subunit vaccines
comprising the head domain of the orthobunyavirus SBV Gc protected mice from clinical symptoms of disease, while a misfolded version of the head domain did not (47).
Here, we demonstrate that immunization of mice with VSV-OROV chimeras generates a strong neutralization serum response against wild-type OROV and that neutralizing serum response correlates with some protection against infection as evidenced by
reduced clinical signs—such as weight loss and a febrile response—although viral
infection was not prevented. Mice remained viremic despite immunization; however,
viral burden in brain samples was decreased. One hypothesis for this result is that
while the vaccines do not appear to be fully protective, they do limit the transmission
of virus across the blood-brain barrier. Although the VSV-OROV constructs appear to
be somewhat protective against wild-type OROV infection, incomplete inhibition suggests that a critical component may be missing.
Analysis of the serum-neutralizing antibody response using linear peptide arrays
identiﬁed four prominent epitopes within the N-terminal region of Gc. All four of those
peptides lie within the head domain of the Gc N-terminal region (16). Recognition of
the OROV head domain ﬁts with earlier work on La Crosse virus (LACV) and SBV that
has also shown that a large proportion of glycoprotein-speciﬁc antibodies are targeted
to the Gc head domain (20, 21) and supports the hypothesis that the head domain of
Gc shields the functionally critical membrane fusion machinery from the antibody
response and thus limits antigenic drift of the core fusion machinery. Immunization of
mice with the puriﬁed head or head and stalk domains of Gc protects against infection
with SBV (16, 47), demonstrating that for some orthobunyaviruses, targeting this
region of Gc may be an effective strategy for vaccine development. Although we did
not directly test whether the N terminus of Gc of OROV can elicit the induction of protective immune responses alone, its loss did not diminish neutralizing serum titers and
instead led to the identiﬁcation of additional epitopes within Gc. Though we observe a
modest distinction in the extent of infection upon challenge of mice immunized with
VSV-OROV and VSV-OROVD4, we do not understand the basis for this distinction.
Development of Oropouche vaccines will require a deeper understanding of correlates
of immune protection, and whether immune protection is achieved following natural
FIG 3 Legend (Continued)
the viruses indicated (n = 3). No neutralization at the highest concentration of sera (1:100) was scored as 1. Statistical analysis was performed
using an unpaired t test (*, P , 0.05; **, P , 0.01; ****, P , 0.0001). (D) Plaque reduction neutralization assays were performed to assess
neutralization of wild-type OROV. Plaques were visually scored after incubation with serial dilutions of mouse serum. Each line (numbered 1
to 5) represents an individual mouse.
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FIG 4 VSV-OROV and VSV-OROVD4 antibodies target Gn and Gc. (A) Schematic of the OROV M segment showing the two
glycoproteins (Gn and Gc) as well as the nonstructural, NSm protein. Peptides identiﬁed in the peptide array with VSV-OROV are
indicated in gray boxes, while peptides identiﬁed in the VSV-OROVD4 peptide array are indicated above the schematic in red lines
and numbers. (B) Heat map of the VSV-OROV peptide array. Analysis of the peptide array was performed with ﬁve VSV-OROV mouse
serum samples, one primary bleed sample, one VSV serum sample, and a sham control. Scale is shown in arbitrary units. (C) Mapping
of the four identiﬁed peptides to the structure of the OROV Gc N-terminal head domain that was determined by Hellert et al. (16) (D)
Peptide array from VSV-OROVD4 sera, like what is shown in panel B for VSV-OROV.
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FIG 5 Prime-boost vaccination of mice with VSV recombinants and challenge with OROV. (A) Inoculation schedule of male, 6-week-old
C57BL/6 mice. Mice were inoculated on day zero with 106 FFU, boosted on day 28 with the same dose, and then challenged 1 week later

(Continued on next page)
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infection. Indeed, while most neutralizing antibodies identiﬁed to date have targeted
bunyaviral glycoproteins, bunyaviral nucleoproteins have also been shown to be
highly immunogenic (48–51). Targeting the nucleoprotein has proved to be an effective method for generating protection in other RNA viruses through both B and T cellmediated immunity, and it will be important to test whether OROV N can also provide
a boost in protection. The VSV-OROV chimeras described here may aid in this analysis
by providing useful BSL2 tools to study Gn and Gc function and their inhibition.

Cell lines. African green monkey Vero cells and BSRT7 Syrian golden hamster kidney cells (generously provided by K. Conzelmann) (52) were maintained at 37°C and 5% CO2 in Dulbecco’s modiﬁed
Eagle medium (DMEM) supplemented with 10% fetal bovine serum (FBS).
VSV recombinant generation, growth, puriﬁcation, and titration. The entire M segment of
OROV BeAn19991 was codon optimized for human cell expression and synthesized using GenScript
(Piscataway, NJ). The OROV M segment was cloned into pVSV-DG-eGFP (39) using the MluI and NotI sites.
To generate OROVD4, site-directed mutagenesis was performed using primers GATATCAACCTGGGCAGG
and CTCGTCGGCGTACACTGT. VSV-OROV and VSV-OROVD4 were generated by transfecting the genomic
plasmid along with plasmids containing VSV N, P, L, and G into BSRT7 cells, as previously described (23).
VSV containing enhanced green ﬂuorescent protein (eGFP) was previously generated (39). All viruses were
grown on BSRT7 cells in DMEM containing 2% FBS and penicillin-streptomycin/kanamycin. The titers of viral
supernatants were determined by plaque assay as previously described (53), or the supernatants were gradient-puriﬁed on a 15 to 45% sucrose gradient and then the titers were determined. GFP-expressing plaques were visualized on a Typhoon 9400 imager. Puriﬁed virus was run on a 10% (wt/vol) acrylamide 0.13%
(wt/vol) bis-acrylamide gel. Gels were stained with Coomassie reagent.
Electron microscopy. VSV and VSV-OROV were deposited onto carbon-coated copper grids and
then stained with 2% (wt/vol) phosphotungstic acid (PTA) in H2O (pH 7.5). A Technai G2 Spirit BioTwin
transmission electron microscope (FEI, Hillsboro, OR) was used to visualize particles. The length and
width of viral particles was measured using ImageJ.
Generation of neutralizing sera. Six-week old male BALB/c mice (Taconic Farms) were injected
intramuscularly (IM) with 105 PFU of VSV, VSV-OROV, VSV-OROVD4, or sham on day 0. On day 27, tail
vein blood samples were collected, and on day 28, mice were boosted with an additional dose of 105
PFU of virus. Then, 7 days later, on day 35, mice were sacriﬁced, and blood samples were collected by
cardiac puncture. Serum was separated by centrifugation at 1,500  g for 10 min at room temperature
and then heated at 56°C for 30 min to inactivate complement.
Serum neutralization assays. Heat-inactivated serum samples from mice were diluted in DMEM in
2-fold dilution series ranging from 1:100 to 1:1,600 in duplicate on a 96-well plate. Then, 100 TCID50 units
of VSV, VSV-OROV, or VSV-OROVD4 were incubated with each serum dilution in wells for 1.5 h at 37°C.
Following incubation of virus and serum, 30,000 BSRT7 cells were added to each well and incubated at
34°C for 48 h. Then, 96-well plates were scanned on a Typhoon FLA9500 imager, and dilutions lacking
any GFP signal were recorded. Neutralization assays were performed three times.
OROV sera peptide arrays. VSV, VSV-OROV, VSV-OROVD4, and sham serum samples were analyzed
using a previously described arboviral peptide array (41, 54).
WT OROV stock production. OROV strain BeAn19991 was originally donated by Luiz Tadeu
Figueiredo and propagated by serial passages in Vero cells by routine methods using DMEM. Virus titration was performed by plaque assay in Vero cells plated at 4  104 cells/well in 48-well plates 1 day prior
to infection. After 1 h of incubation with virus, cells were replenished with DMEM supplemented with
2% vol/vol FBS, 1% vol/vol antibiotics, and 1% vol/vol carboxymethyl cellulose (CMC) (Sigma-Aldrich)
and incubated at 37°C and 5% CO2 for 4 days. Cells were ﬁxed with 4% formaldehyde for 20 min at room
temperature, washed in phosphate buffered saline (PBS) (Gibco), and stained with 20% vol/vol ethanolviolet crystal solution for 15 min.
OROV PRNT50. The titer of neutralizing antibodies was determined on serum obtained on day 28 after immunization with VSV, VSV-OROV, or VSV-OROVD4 mice by a standard plaque reduction neutralization assay. Plaques were scored visually after incubation with serial dilutions of the mouse serum, and
the 50% plaque reduction neutralization titer (PRNT50) was determined (55).
Immunization and OROV challenge. A total of 25 male C57BL/6 6-week-old mice were assigned to
5 groups; two sham groups were administered sterile 1 PBS, and three groups were immunized with
VSV, VSV-OROV, or VSV-OROVD4. Injections were made subcutaneously in the dorsal lumbar area with
106 focus-forming units (FFU) in a volume of 50 m l. At 28 days postvaccination, a booster immunization
was administered to animals with the same virus dose or volume of PBS. One week later, the VSV recombinant-immunized and one sham-inoculated group were challenged with 106 TCID50 OROV wild-type BeAn19991

FIG 5 Legend (Continued)
with 106 TCID50 OROV (ﬁve mice per group). One week after challenge, mice were sacriﬁced. (B) Body weight (top) and temperature
(bottom) were assessed each day following challenge with OROV. *, P , 0.001. (C) One day before challenge, VSV-OROV, VSV-OROVD4, and
VSV sera were collected from mice and tested for neutralization of OROV. Each line (numbered 1 to 5) represents an individual mouse. (D)
Viral loads were assessed by measuring S segment copies in blood and brain samples from mice following sacriﬁce. Brain samples were
normalized to the internal control, HRPT1. *, P , 0.05.
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subcutaneously. The other sham-inoculated group was mock-injected. Mice were followed for weight loss and
temperature variation once per day for 7 days following challenge. All injections with virus were performed
under anesthesia of 1.5% isoﬂurane.
WT OROV serum and organ sampling. Serum from animals was collected by retrieving blood from
the caudal vein. Total blood was centrifuged at 2500  g for 5 min, and clear serum was collected. Seven
days after challenge, mice were sacriﬁced and perfused through the ascending aorta with sterile PBS
(pH 7.4). Brain and blood were collected under aseptic conditions.
RT qPCR. Tissues were dissected, weighed, and homogenized in sterile PBS using a TissueLyser II instrument (Qiagen). For viral RNA quantiﬁcation, samples were extracted using a QIAamp viral RNA minikit
(Qiagen) according to the manufacturer’s recommendations. Reverse transcription was performed using
random primers and the high-capacity reverse transcriptase kit (Thermo Fisher) according to manufacturer’s
instructions. Primers were designed to detect a 100-bp region of OROV nucleocapsid from the small segment (S-OROV-reverse: 59-TTGCGTCACCATCATTCCAA-39; S-OROV-forward: 59-TACCCAGATGCGATCACCAA39), using SYBR green (Kappa Biosystems). Blood samples were normalized to total volume extracted,
and brain samples were normalized to the internal control HRPT1. The reaction was performed in the
StepOnePlus PCR system (Applied Biosystems). Standard curves were generated using a plasmid containing the entire OROV small-segment antigenome (pTVT-S described in [3]). Each sample was
assayed in duplicate, and the mean value was plotted (3).
Statistical analysis. Differences in particle sizes and between VSV and VSV-OROV sera or VSVOROVD4 sera were analyzed using an unpaired t test. Body weight and temperature in mouse challenge
experiments were compared using a two-way analysis of variance (ANOVA). Differences in brain virus
titers were analyzed using the Kruskal-Wallis test. All analysis was performed with GraphPad Prism.
Animal use and ethical statement. All VSV recombinant animal experiments and housing were
conducted in accordance with protocols approved by the Harvard Medical Area Standing Committee on
Animals. All WT OROV studies were approved by the University of São Paulo Committee on Care and
Use of Laboratory Animals (protocol no. 194/2019). The 6-week-old C57BL/6 mice were obtained from
the Central Animal Facility of the University of São Paulo, School of Medicine, in Ribeirão Preto, SP,
Brazil. Infected animals were maintained in the Virology Research Center-FMRP USP animal facility. All
animals were kept in accordance with guidelines of the University of São Paulo Committee on Care and
Use of Laboratory Animals.
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